Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Community-based randomized controlled trial of diabetes prevention study for high-risk individuals of type 2 diabetes: lifestyle intervention using web-based system.

Cha SA, Lim SY, Kim KR, Lee EY, Kang B, Choi YH, Yoon KH, Ahn YB, Lee JH, Ko SH.

BMC Public Health. 2017 May 5;17(1):387. doi: 10.1186/s12889-017-4283-y.

2.

Réfutation : Les médecins de famille devraient-ils prescrire des médicaments contre l’obésité? OUI.

Bourns L, Shiau J.

Can Fam Physician. 2017 Feb;63(2):e84. French. No abstract available.

PMID:
28209695
Free PMC Article
3.

Rebuttal: Should family physicians prescribe medication for obesity? YES.

Bourns L, Shiau J.

Can Fam Physician. 2017 Feb;63(2):e82. No abstract available.

5.

Women's Perceived Reasons for Their Excessive Postpartum Weight Retention: A Qualitative Interview Study.

Christenson A, Johansson E, Reynisdottir S, Torgerson J, Hemmingsson E.

PLoS One. 2016 Dec 9;11(12):e0167731. doi: 10.1371/journal.pone.0167731. eCollection 2016.

6.

Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial.

Stenman LK, Lehtinen MJ, Meland N, Christensen JE, Yeung N, Saarinen MT, Courtney M, Burcelin R, Lähdeaho ML, Linros J, Apter D, Scheinin M, Kloster Smerud H, Rissanen A, Lahtinen S.

EBioMedicine. 2016 Nov;13:190-200. doi: 10.1016/j.ebiom.2016.10.036. Epub 2016 Oct 26.

7.

Obesity: Current and potential pharmacotherapeutics and targets.

Narayanaswami V, Dwoskin LP.

Pharmacol Ther. 2017 Feb;170:116-147. doi: 10.1016/j.pharmthera.2016.10.015. Epub 2016 Oct 20. Review.

PMID:
27773782
8.
9.

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.

Isidro ML, Cordido F.

Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145. Review.

10.

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2016 Jul;39(7):1186-201. doi: 10.2337/dc16-0873. Epub 2016 Jun 9.

11.

Standards of care for type 2 diabetes in China.

Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, Zhu D, Chen L, Chen L, Guo L, Guo X, Ji Q, Li Q, Li X, Liu J, Ran X, Shan Z, Shi L, Song G, Yang L, Yang Y, Yang W; Chinese Diabetes Society.

Diabetes Metab Res Rev. 2016 Jul;32(5):442-58. doi: 10.1002/dmrr.2827. No abstract available.

12.

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Rosenblit PD.

Cardiovasc Diabetol. 2016 Jul 14;15:95. doi: 10.1186/s12933-016-0412-7. Review.

13.

Through Thick and Thin: Identifying Barriers to Bariatric Surgery, Weight Loss Maintenance, and Tailoring Obesity Treatment for the Future.

Westerveld D, Yang D.

Surg Res Pract. 2016;2016:8616581. doi: 10.1155/2016/8616581. Epub 2016 May 23. Review.

14.

Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.

Brannick B, Wynn A, Dagogo-Jack S.

Exp Biol Med (Maywood). 2016 Jun;241(12):1323-31. doi: 10.1177/1535370216654227. Review.

15.

Gender-related affecting factors of prediabetes on its 10-year outcome.

Song X, Qiu M, Zhang X, Wang H, Tong W, Ju L, Gu L, Sun S, Zhang H, Wang W, Tian J.

BMJ Open Diabetes Res Care. 2016 May 10;4(1):e000169. doi: 10.1136/bmjdrc-2015-000169. eCollection 2016.

16.

Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.

Hodkinson A, Gamble C, Smith CT.

Trials. 2016 Apr 22;17(1):207. doi: 10.1186/s13063-016-1327-z. Review.

17.

Diabetes Dyslipidemia.

Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H.

Diabetes Ther. 2016 Jun;7(2):203-19. doi: 10.1007/s13300-016-0167-x. Epub 2016 Apr 7. Review.

18.

Long-term weight loss maintenance for obesity: a multidisciplinary approach.

Montesi L, El Ghoch M, Brodosi L, Calugi S, Marchesini G, Dalle Grave R.

Diabetes Metab Syndr Obes. 2016 Feb 26;9:37-46. doi: 10.2147/DMSO.S89836. eCollection 2016. Review.

19.

The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.

Crane J, McGowan B.

Ther Adv Chronic Dis. 2016 Mar;7(2):92-107. doi: 10.1177/2040622315620180. Epub 2015 Dec 16. Review.

20.

The metabolic vascular syndrome - guide to an individualized treatment.

Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL.

Rev Endocr Metab Disord. 2016 Mar;17(1):5-17. doi: 10.1007/s11154-016-9345-4. Review.

Supplemental Content

Support Center